|
[Related PubMed/MEDLINE]
Total Number of Papers: 1116
|
|
|
|
|
[Display Entries]
|
|
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
|
Page: of
|
|
|
|
| Abbreviation |
: IL-5 |
| Long Form |
: interleukin-5 |
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2020 |
A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting. |
--- |
| 2 |
2020 |
A randomized, placebo-controlled, double-blind pilot study of single-dose humanized anti-IL5 antibody (reslizumab) for the reduction of eosinophilia following diethylcarbamazine treatment of Loa loa infection. |
AEC, DEC, mf |
| 3 |
2020 |
Altered plasma cytokine levels in acute and chronic central serous chorioretinopathy. |
CSC, CT, IL-6, TNF-alpha, VEGF |
| 4 |
2020 |
Beliefs and preferences regarding biological treatments for severe asthma. |
INESNET |
| 5 |
2020 |
Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis. |
EGPA, IL-5R |
| 6 |
2020 |
Citrus flavonoids suppress IL-5 and ROS through distinct pathways in PMA/ionomycin-induced EL-4 cells. |
--- |
| 7 |
2020 |
Correlation of mucus inflammatory proteins and olfaction in chronic rhinosinusitis. |
CCL2, CRS, CRSsNP, CRSwNP, CT, CXCL5, IgE, OC, TDI, TNF-alpha |
| 8 |
2020 |
Correlation of Nasal Fluid Biomarkers and Symptoms in Patients with Persistent Allergic Rhinitis. |
ARIA, CC16, ELISA, NALF, PAR, TNSS |
| 9 |
2020 |
Customizable Multiplex Antibody Array Immunoassays with Attomolar Sensitivities. |
ELISA, IL-10, IL-22, IL-6, TNF-alpha |
| 10 |
2020 |
Distinct immune phenotypes in infants developing asthma during childhood. |
--- |
| 11 |
2020 |
Effectiveness and safety of benralizumab for severe asthma in clinical practice (J-BEST): a prospective study. |
ACT, AQLQ, FeNO, FEV1, OCS |
| 12 |
2020 |
Effects of interferon and glatiramer acetate on cytokine patterns in multiple sclerosis patients. |
GA, IFN-gamma, MS, RR, TGF-beta |
| 13 |
2020 |
Evaluation of C-C Chemokine Ligand 5 (CCL5) Chemokine, Interleukin 5 (IL-5) Cytokine, and Eosinophil Counts as Potential Biomarkers in Saudi Patients with Chronic Asthma During Sandstorms. |
CCL5, ELISA, IgE |
| 14 |
2020 |
Identification of serum biomarker panel to differentiate malignant from benign thyroid nodules using multiplex bead assay. |
AUC, EGF, HGF, IL-8, VDRP |
| 15 |
2020 |
Immune Response in Young Thoroughbred Racehorses under Training. |
Hct, IFN-gamma, IL-1beta, IL-2, IL-3, IL-4, IL-6, IL-8, MCH, MCHC, MCV, RDW-SD, TGF-beta, TNF-alpha |
| 16 |
2020 |
Interleukin-5 deletion promotes sepsis-induced M1 macrophage differentiation, deteriorates cardiac dysfunction, and exacerbates cardiac injury via the NF-kappaB p65 pathway in mice. |
LPS, NF-kappaB |
| 17 |
2020 |
Interleukin-5-producing malignant pleural mesothelioma with eosinophilic pleural effusion. |
--- |
| 18 |
2020 |
Longitudinal analyses reveal immunological misfiring in severe COVID-19. |
COVID-19 |
| 19 |
2020 |
Massive atelectasis by mucoid impaction in an asthma patient during treatment with anti-interleukin-5 receptor antibody. |
--- |
| 20 |
2020 |
Mepolizumab: an alternative therapy for idiopathic chronic eosinophilic pneumonia with glucocorticoid intolerance. |
ICEP |
| 21 |
2020 |
Mesenchymal PGD2 activates an ILC2-Treg axis to promote proliferation of normal and malignant HSPCs. |
AML, COX, HSPCs, MSCs, PGs |
| 22 |
2020 |
Nicotinamide inhibits melanoma in vitro and in vivo. |
ATP, IFN, IFN-gamma, IL-10, IL-3, NAM, RANTES, ROS |
| 23 |
2020 |
Particle depletion of diesel exhaust restores allergen-induced lung-protective surfactant protein D in human lungs. |
BAL, CC16, DE, PDDE, SP-D |
| 24 |
2020 |
PD-1 expression affects cytokine production by ILC2 and is influenced by peroxisome proliferator-activated receptor-gamma. |
ILCs, PPARgamma |
| 25 |
2020 |
Pharmacogenetic investigation of efficacy response to mepolizumab in eosinophilic granulomatosis with polyangiitis. |
EGPA |
| 26 |
2020 |
Potential anti-inflammatory and immunomodulatory effects of carvacrol against ovalbumin-induced asthma in rats. |
AEC, BALF, DEXA, IFN-gamma, IgE, IL-13, IL-4, iNOS, MDA, OVA, SOD, TNF-alpha |
| 27 |
2020 |
Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma. |
--- |
| 28 |
2020 |
Real-life experience with benralizumab during 6 months. |
ACT |
| 29 |
2020 |
Selective AhR knockout in langerin-expressing cells abates Langerhans cells and polarizes Th2/Tr1 in epicutaneous protein sensitization. |
AhR, DC, IgE, IL-13, LC, LN, Th2, Tr1 |
| 30 |
2020 |
Significant improvement in lung function and asthma control after benralizumab treatment for severe refractory eosinophilic asthma. |
ACQ, CRSwNP, OCS, SRA, TSLP |
| 31 |
2020 |
Surface-modified mesoporous nanofibers for microfluidic immunosensor with an ultra-sensitivity and high signal-to-noise ratio. |
OPA, PEO-PPO-PEO |
| 32 |
2020 |
The Current State of Biologic Therapies for Treatment of Refractory Asthma. |
FDA, IgE |
| 33 |
2020 |
Usefulness of lymphocyte transformation test and in vitro cytokine release in differentiating between independent and cross-reacting nickel/palladium allergy. |
LTT, Ni, Pd, PT |
| 34 |
2020 |
Zoledronic Acid Abrogates Restraint Stress-Induced Macrophage Infiltration, PDGF-AA Expression, and Ovarian Cancer Growth. |
GM-CSF, MIF, PDGF-AA, TfR, VEGF |
| 35 |
2020 |
[Effect of Huai Qi Huang on asthma in rats and the mechanism research]. |
BALF, HQH, IgE, IL-10, IL-3, IL-4, INF-gamma |
| 36 |
2019 |
Active vaccination against interleukin-5 as long-term treatment for insect-bite hypersensitivity in horses. |
eIL-5, IBH, VLP |
| 37 |
2019 |
Application of Inflammatory Markers in Induced Sputum in Stable Chronic Obstructive Pulmonary Disease Patients with Positive Bronchodilation Tests. |
BD, COPD, ECP, MPO |
| 38 |
2019 |
Chemokines and Growth Factors Produced by Lymphocytes in the Incompetent Great Saphenous Vein. |
CVD, FGF, G-CSF, GFs, GM-CSF, GSV, IL-8, MCP-1, MIP-1A and MIP-1B, PDGF-BB, PHA, VEGF |
| 39 |
2019 |
Chronic, Active Inflammation in Patients With Failed Total Knee Replacements Undergoing Revision Surgery. |
GM-CSF, OA, SF, TKA |
| 40 |
2019 |
Cyanidin-3-O-beta-glucoside attenuates allergic airway inflammation by modulating the IL-4Ralpha-STAT6 signaling pathway in a murine asthma model. |
BALF, Cy-3-g, IL-13, IL-4, IL-4Ralpha, OVA, STAT6, Th2 |
| 41 |
2019 |
Effectiveness and safety of mepolizumab in severe refractory eosinophilic asthma: results in clinical practice. |
OCS |
| 42 |
2019 |
Effects of catalpol on bronchial asthma and its relationship with cytokines. |
BALF, IFN-gamma, IL-4 |
| 43 |
2019 |
Effects of miR-26a/miR-146a/miR-31 on airway inflammation of asthma mice and asthma children. |
ELISA, miR-26a, RT-PCR, TNF-alpha |
| 44 |
2019 |
Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma. |
OCS |
| 45 |
2019 |
Efficacy and steroid-sparing effect of benralizumab: has it an advantage over its competitors? |
HRQoL, OCS |
| 46 |
2019 |
Evaluation of Immunogenic Effect of Toxoplasma gondii Recombinant SAG-1 Antigen with Propranolol as Adjuvant in BALB/c Mice. |
IFN-gamma, rSAG-1, TLA |
| 47 |
2019 |
Genome-Wide Scan Identifies Selection Signatures in Chinese Wagyu Cattle Using a High-Density SNP Array. |
ADAM12, ALAS1, CAPN1, FAM110A, FGF14, GO, GRIK2, HSD17B7, IGF2R, LHX6, NOS1AP, PAX6, PRDM9, QTL, RORA, RPAP3, RXFP4, SMIM13, SNX29, TAFA1, TLR9, WDR7, ZIM2 |
| 48 |
2019 |
Higher Binding Affinity and in vitro Potency of Reslizumab for Interleukin-5 Compared With Mepolizumab. |
--- |
| 49 |
2019 |
IL-5 Exposure In Utero Increases Lung Nerve Density and Airway Reactivity in Adult Offspring. |
--- |
| 50 |
2019 |
Inhibitory effects of catalpol coordinated with budesonide and their relationship with cytokines and Interleukin-13 expression. |
BALF, BUD, IFN-gamma, IL-13, IL-4 |
| 51 |
2019 |
Interleukin-5 in the Pathophysiology of Severe Asthma. |
--- |
| 52 |
2019 |
Maternal deprivation increases microglial activation and neuroinflammatory markers in the prefrontal cortex and hippocampus of infant rats. |
CD11B, INF-gamma, MD, MIP, PFC, PND, TLR |
| 53 |
2019 |
Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. |
ANCA, EGPA |
| 54 |
2019 |
Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease. |
--- |
| 55 |
2019 |
Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma. |
GINA, IgE, IL-4Ralpha, IL-5R, OCS |
| 56 |
2019 |
Protective effects of betulinic acid on intestinal mucosal injury induced by cyclophosphamide in mice. |
BA, CYP, MDA, MIP-1alpha, MIP-1beta, RANTES, SOD, TNF-alpha, ZO-1 |
| 57 |
2019 |
Protective effects of betulinic acid on intestinal mucosal injury induced by cyclophosphamide in mice. |
BA, CYP, MDA, RANTES, SOD, TNF-alpha, ZO-1 |
| 58 |
2019 |
Pulegone inhibits inflammation via suppression of NLRP3 inflammasome and reducing cytokine production in mice. |
GM-CSF, IFN-gamma, IL-18, IL-1beta, LPS, M-CSF, MCP-1, MIP-1beta, NLRP3, TNF-alpha |
| 59 |
2019 |
Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose. |
ACT, ADCC, FEV1, OCS, PEF |
| 60 |
2019 |
Role of coaggregation in the pathogenicity and prolonged colonisation of Vibrio cholerae. |
AI-2, IL-10 |
| 61 |
2019 |
Safety and Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis. |
EGPA |
| 62 |
2019 |
Selection and characterization of single-stranded DNA aptamers against interleukin-5. |
SELEX |
| 63 |
2019 |
Serum Levels of Epithelial-Derived Cytokines as Interleukin-25 and Thymic Stromal Lymphopoietin after a Single Dose of Mepolizumab in Patients with Severe Non-Allergic Eosinophilic Asthma: A Short Report. |
FeNO, IL-25, SNEA, TSLP |
| 64 |
2019 |
Single-cell Analysis of CAR-T Cell Activation Reveals A Mixed TH1/TH2 Response Independent of Differentiation. |
CAR, GM-CSF, Th |
| 65 |
2019 |
Structural Basis of Interleukin-5 Inhibition by the Small Cyclic Peptide AF17121. |
--- |
| 66 |
2019 |
The ethanol extract of Involcucrum castaneae ameliorated ovalbumin-induced airway inflammation and smooth muscle thickening in guinea pigs. |
BALF, EEIC, ELISA, EOS, IC, IFN-gamma, IgE, NGF, OVA, PB, RT-PCR |
| 67 |
2019 |
The relationship between inflammatory markers and spirometric parameters in ACOS, Asthma, and COPD. |
COPD, CysLTs, PGD2, PGE2 |
| 68 |
2019 |
Toll-like receptor 4 activation on human amniotic epithelial cells is a risk factor for pregnancy loss. |
hAECs, LPS, PGE2, TGF-beta1, TLRs, TNF-alpha |
| 69 |
2019 |
Trib1 regulates eosinophil lineage commitment and identity by restraining the neutrophil program. |
EoPs, GMP, HSCs, Trib1 |
| 70 |
2019 |
World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management. |
CEL, NOS, HES |
| 71 |
2019 |
[Benralizumab: Targeting the IL-5 Receptor in Severe Eosinophilic Asthma]. |
--- |
| 72 |
2019 |
[Clinical and economic analysis of Reslizumab use in the treatment of patients with severe allergic eosinophilic asthma]. |
mAb |
| 73 |
2019 |
[Expression of immunological and inflammatory biomarkers in chronic rhinosinusitis with nasal polyps and its predictive value for recurrence]. |
CRSwNP, ECP/MPO, ROC, TIMP1 |
| 74 |
2019 |
[Levels of airway inflammatory mediators in peripheral blood in infants and young children with wheezing]. |
EOS, IL-13, IL-2, IL-4, TGF-beta1, Th1, Th2, tIgE |
| 75 |
2019 |
[The protective effect of interleukin-5 in septic mice]. |
BUN, cTnI, SCr, TNF-alpha |
| 76 |
2018 |
Activation state of circulating eosinophils in nasal polyposis. |
CRSwNP, MFI |
| 77 |
2018 |
Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma. |
--- |
| 78 |
2018 |
Anti-IL-5 therapy in patients with severe eosinophilic asthma - clinical efficacy and possible criteria for treatment response. |
--- |
| 79 |
2018 |
Benralizumab for the add-on maintenance treatment of patients with severe asthma aged 12years and older with an eosinophilic phenotype. |
--- |
| 80 |
2018 |
Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma. |
FDA, Th2 |
| 81 |
2018 |
Bone marrow type 2 innate lymphoid cells: a local source of interleukin-5 in interleukin-33-driven eosinophilia. |
--- |
| 82 |
2018 |
Characterisation of the porcine cytokines which activate the CD131betac common sub-unit, for potential immune-augmentation. |
5-FU, BM, GM-CSF, HSC, IL-3, IM, po, rPo |
| 83 |
2018 |
Characterizing the course of suicidal ideation response to ketamine. |
MDD, SI |
| 84 |
2018 |
Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma - a systematic review and meta-analysis. |
MCID, OCS |
| 85 |
2018 |
EPO modified MSCs can inhibit asthmatic airway remodeling in an animal model. |
BALF, EPO, IL-13, IL-4, MSCs, p38 MAPK, TAK1, TGF-beta1 |
| 86 |
2018 |
Expressions of Eotaxin-3, Interleukin-5, and Eosinophil-Derived Neurotoxin in Chronic Subdural Hematoma Fluids. |
CSDHs, CSF, EDN |
| 87 |
2018 |
Highlights of eosinophilic chronic rhinosinusitis with nasal polyps in definition, prognosis, and advancement. |
CRSwNP |
| 88 |
2018 |
Host- and Helminth-Derived Endocannabinoids That Have Effects on Host Immunity Are Generated during Infection. |
2-AG, AEA, OEA |
| 89 |
2018 |
Human Adipose Tissue-Derived Mesenchymal Stem Cells Attenuate Atopic Dermatitis by Regulating the Expression of MIP-2, miR-122a-SOCS1 Axis, and Th1/Th2 Responses. |
AD, AD-MSCs, CD163, HDAC3, iNOS, MCs, MIP-1ss, SOCS1, Th1, Th2, Treg |
| 90 |
2018 |
Identification of Adult Mesodermal Progenitor Cells and Hierarchy in Atherosclerotic Vascular Calcification. |
BM, IL-1beta |
| 91 |
2018 |
IFN-gamma and IL-5 whole blood response directed against mycolactone polyketide synthase domains in patients with Mycobacterium ulcerans infection. |
ACP3, Ag85A, IFN-gamma, KS C, PKS, RPMI |
| 92 |
2018 |
Interleukin-5 suppresses Vascular Endothelial Growth Factor-induced angiogenesis through STAT5 signaling. |
HMVEC-L, KD |
| 93 |
2018 |
Membrane Vesicles Derived from Bordetella bronchiseptica: Active Constituent of a New Vaccine against Infections Caused by This Pathogen. |
OmpC, OMVs |
| 94 |
2018 |
Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. |
ANCA, EGPA |
| 95 |
2018 |
Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study. |
ACT |
| 96 |
2018 |
RORalpha-expressing T regulatory cells restrain allergic skin inflammation. |
DR3, RORalpha, Th2, TL1A, TNF |
| 97 |
2018 |
Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma. |
IL-5Ralpha |
| 98 |
2018 |
The Prospects of an Active Vaccine Against Asthma Targeting IL-5. |
mAbs |
| 99 |
2018 |
TSLP signaling in CD4+ T cells programs a pathogenic T helper 2 cell state. |
Th2, TSLP |
| 100 |
2017 |
Anti-IL5 therapies for asthma. |
ACQ, AQLQ, HRQoL, ICS, IL-5R, SGRQ |
|
A Search Service for Abbreviation / Long Form
